Atıf İçin Kopyala
Korkmaz S., Dal M. S., Berber I., Sahin D. G., Dogu M. H., Ayyildiz O., ...Daha Fazla
GERIATRICS & GERONTOLOGY INTERNATIONAL, cilt.15, sa.6, ss.729-735, 2015 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
15
Sayı:
6
-
Basım Tarihi:
2015
-
Doi Numarası:
10.1111/ggi.12341
-
Dergi Adı:
GERIATRICS & GERONTOLOGY INTERNATIONAL
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
-
Sayfa Sayıları:
ss.729-735
-
Anahtar Kelimeler:
chronic myeloid leukemia, dasatinib, elderly patients, imatinib, nilotinib, CHRONIC-PHASE, MYELOPROLIFERATIVE DISORDERS, 1ST-LINE TREATMENT, IMATINIB TREATMENT, CML, INTERFERON, RECOMMENDATIONS, CYTARABINE, MANAGEMENT, NILOTINIB
-
Van Yüzüncü Yıl Üniversitesi Adresli:
Evet
Özet
AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy.